Home

NICE gives go-ahead for Lucentis

2008-08-27T12:02:00

The National Institute for Health and Clinical Excellence has said primary care trusts should fund the use of ranibizumab - commonly known as Lucentis - for the treatment of wet age-related macular degeneration if certain conditions apply.

You need to be a subscriber to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All HSJ news by sector, topic & region
  • Breaking News announcements
  • App for mobile and offline reading
  • Comment and Daily Insights newsletters
  • Regional roundup newsletters
  • Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant
  • 10 expert briefings every fortnight (Premium only)

Subscribe

to HSJ

Already a subscriber? Sign into your account here